Open AccessDiagnostics of contrastinduated nephropathy after percutaneous coronary intervention
Author(s) -
А. В. Пырочкин,
А. М. Пристром,
Valery Pilotovich,
Д. Н. Горецкая,
Т. М. Юрага,
Т. Д. Борисенко,
Е. А. Воробьева,
О. М. Соловей,
П. Ф. Черноглаз,
В. В. Веселов,
И. Е. Лушникова,
С. Е. Пискунов
Publication year - 2019
Publication title -
vescì nacyânalʹnaj akadèmìì navuk belarusì. seryâ medycynskìh navuk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 1
eISSN - 2524-2350
pISSN - 1814-6023
DOI - 10.29235/1814-6023-2019-16-2-175-184
Subject(s) - medicine , cystatin c , creatinine , percutaneous coronary intervention , beta 2 microglobulin , coronary angiography , nephropathy , lipocalin , acute kidney injury , cardiology , percutaneous , urinary system , myocardial infarction , endocrinology , diabetes mellitus
The present study is devoted to search for the opportunities of early diagnosis of the development of contrastinduced nephropathy when performing coronary angiography and percutaneous coronary intervention in patients with a chronic ischemic heart disease. The predicative ability of modern biomarkers was studied in comparison with serum creatinine. Baseline serum β2-microglobulin levels >1.1 mg/l can be attributed to patients at a high risk of developing complications. Increasing the level of cystatin C in the blood by 25 % from baseline after 24 hours or >1.064 mg/l, increasing the level of β2-microglobulin in blood after 24 hours > 1.42 mg/l allows you to diagnose acute kidney damage, before the creatinine dynamics and can be used in routine clinical practice. The determination of neutrophil lipocalin in the urine improves the accuracy of diagnosis, but is difficult in routine practice.